28788-62-7

Basic information

• Product Name: 4-N-BUTYLBENZOYL CHLORIDE
• Synonyms: 4-Butylbenzoic acid chloride;4-Butylbenzoyl chloride,99%;4-(But-1-yl)benzoyl chloride;4-N-BUTYLBENZOYL CHLORIDE;4-BUTYLBENZENE-1-CARBONYL CHLORIDE;4-BUTYLBENZOYL CHLORIDE;P-BUTYLBENZOYL CHLORIDE;4-butyl-benzoylchlorid
• CAS NO: 28788-62-7
• Molecular Formula: C₁₁H₁₃ClO
• Molecular Weight: 196.67
• EINECS: 249-224-2
• Product Categories: Building Blocks for Liquid Crystals;Chalcones, etc. (Building Blocks for Liquid Crystals);Functional Materials;Acid Halides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 28788-62-7.mol

Chemical Properties

• Boiling Point: 155-156 °C22 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: clear slightly yellow liquid
• Density: 1.051 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00655mmHg at 25°C
• Refractive Index: n20/D 1.5351(lit.)
• Water Solubility: Reacts with water.
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 4-N-BUTYLBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-BUTYLBENZOYL CHLORIDE(28788-62-7)
• EPA Substance Registry System: 4-N-BUTYLBENZOYL CHLORIDE(28788-62-7)

Safety Data

• Hazard Codes: C
• Statements: 34-36/37
• Safety Statements: 26-27-28-36/37/39-45
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• TSCA: Yes
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 28788-62-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
4-N-Butylbenzoyl Chloride is used as a chemical intermediate for the synthesis of 2,5-bis[(4-butylbenzoyl)oxy]styrene (BBOS, monomer). This monomer is a key component in the production of certain polymers and materials with specific properties.
Used in Liquid Crystals Industry:
4-N-Butylbenzoyl Chloride is also used as an intermediate in the production of liquid crystals. Liquid crystals are widely used in various applications, including display technologies and optical devices, due to their unique properties.

InChI:InChI=1/C11H13ClO/c1-2-3-4-9-5-7-10(8-6-9)11(12)13/h5-8H,2-4H2,1H3

Upstream product

• 20651-71-2 4-butyl benzoic acid 
• 79-37-8 oxalyl dichloride 
• 104-51-8 1-butylbenzene 
• 201230-82-2 carbon monoxide 
• 41492-05-1 p-bromobutylbenzene 

Downstream Products

• 111028-85-4 4'-butyl-2,3,5,6-tetramethyl-benzophenone 
• 107377-07-1 4-n-butylbenzamide 
• 64357-57-9 (4-Butyl-phenyl)-(4-fluoro-2-methyl-phenyl)-methanone 
• 64357-86-4 (4-Butyl-phenyl)-(4-heptyl-phenyl)-methanone 
• 64357-88-6 (4-Butyl-phenyl)-(4-nonyl-phenyl)-methanone 
• 64408-87-3 4-Butyl-thiobenzoic acid S-(4-hexyloxy-phenyl) ester 
• 64408-88-4 4-Butyl-thiobenzoic acid S-(4-cyano-phenyl) ester 
• 72997-58-1 2-(4-butyl-phenyl)-5-(4-methoxy-phenyl)-thiazole 
• 61733-45-7 4-n-butylbenzoic acid 4'-(4-n-hexylphenyl)-phenyl ester 
• 59748-34-4 4'-pentyl(1,1'-biphenyl)-4-yl 4-butylbenzoate 
• 59748-32-2 4'-propyl(1,1'-biphenyl)-4-yl 4-butylbenzoate 
• 59748-33-3 4-n-butylbenzoic acid 4'-(4-n-butylphenyl)-phenyl ester 
• 35684-23-2 4-Methoxyphenyl-4'-n-butylbenzoat 
• 123769-41-5 (4-Butyl-phenyl)-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-methanone 

Relevant articles and documents

O-Alkyl Hydroxamates Display Potent and Selective Antileishmanial Activity

Leishmania (L.) infantum causes visceral, cutaneous, and mucosal leishmaniasis in humans and canine leishmaniasis in dogs. Herein, we describe that O-alkyl hydroxamate derivatives displayed potent and selective in vitro activity against the amastigote stage of L. infantum while no activity was observed against promastigotes. Compound 5 showed potent in vivo activity against L. infantum. Moreover, the combination of compound 5 supported on gold nanoparticles and meglumine antimoniate was also effective in vivo and improved the activity of these compounds compared to that of the individual treatment. Docking studies showed that compound 5 did not reach highly conserved pocket C and established interactions with the semiconserved residues V44, A45, R242, and E243 in pocket A of LiSIR2rp1. The surface space determined by these four amino acids is not conserved in human sirtuins. Compound 5 represents a new class of selective ligands with antileishmanial activity.

Lappaconitine derivative with analgesic activity, and preparation method and application thereof

The invention provides a lappaconitine derivative with analgesic activity, and a preparation method and application thereof. The structure of the lappaconitine derivative is as shown in formula I in the specification. The lappaconitine derivative provided by the invention is high in analgesic activity, good in water solubility and low in biotoxicity, can be used for preparing low-toxicity analgesic drugs, and is wide in application prospect.

Ni-Catalyzed Direct Carboxylation of Aryl C?H Bonds in Benzamides with CO2

The direct carboxylation of inert aryl C?H bond catalyzed by abundant and cheap nickel is still facing challenge. Herein, we report the Ni-catalyzed direct carboxylation of aryl C?H bonds in benzamides under 1 atm of CO2 to afford various methyl carboxylates or phthalimides, dealing with different post-processing. The reaction displays excellent functional group tolerance and affords moderate to high carboxylation yields under mild conditions. Detail mechanistic studies suggest that a Ni(0)?Ni(II)?Ni(I) catalytic cycle may be involved in this reaction. (Figure presented.).

Synthesis and molecular docking studies of some novel antimicrobial benzamides

Common use of classical antibiotics has caused to the growing emergence of many resistant strains of pathogenic bacteria. Therefore, we aimed to synthesize a number of N-(2-hydroxy-(4 or 5)-nitrophenyl)benzamide derivatives as a new class of antimicrobial compounds. Moreover, our second goal is to predict the interaction between active structures and enzymes (DNA –gyrase and FtsA) in the binding mode. In this study, thirteen N-(2-hydroxy-(4 or 5-nitrophenyl)-substituted-benzamides were synthesized and determined for their antimicrobial activity using the microdilution method. According to this work, none of the compounds showed any activity against Candida albicans and its clinical isolate. Some of the benzamides (4N1, 5N1, 5N2) displayed very significant activity against Staphylococcus aureus and MSSA with 4 μg/ml MIC value, even they were found to be more potent than ceftazidime. 4N1 was also found to be more effective than gentamicin against Enterococcus faecalis clinical isolate. Molecular docking studies revealed that 4N1, 5N1, and 5N2 showed a good interactions with DNA-gyrase. Moreover, 5N1 has interacted with FtsA enzyme in the binding mode, as well. Only compound 5N4 displayed very good activity against Escherichia coli ATCC 25922. These findings showed us that 4N1, 5N1, 5N2, and 5N4 could be lead compounds to discover new antibacterial candidates against multidrug-resistant strains.

Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent

The invention relates to Mycobacterium tuberculosis-thioredoxin reductase inhibitors, processes for the preparation thereof, drugs containing said compounds, and the use of said compounds for manufacturing drugs.

4-butyl polyhydroxy benzophenone compound derivative and application thereof

The invention belongs to the field of medicines, and particularly relates to a 4-butyl polyhydroxy benzophenone compound derivative which is used as a medicine for preventing and treating oxidative stress injury, reducing blood fat and protecting liver. The chemical general formula of the derivative is described in the specification, wherein R1 is selected from n-butyl, isobutyl or tert-butyl, R2is selected from hydrogen, hydroxyl or halogen, R3 is selected from hydrogen, hydroxyl or carboxylic ester, R4 is selected from hydrogen, hydroxyl or carboxylic ester, R5 is selected from hydrogen orhydroxyl, and R6 is selected from hydrogen, hydroxyl or halogen. According to the 4-butyl polyhydroxy benzophenone compound derivative provided by the invention, the protection rate of most compoundson injured cells is higher than 90%, and the antioxidant activity and the protection rate on the injured cells are remarkably different from those of natural animal and plant extracts applied to the market at present. The 4-butyl polyhydroxy benzophenone compound derivative provided by the invention has a remarkable liver protection effect, not only has an inhibition effect on adipogenesis, but also has a remarkable improvement effect on liver injury caused by NAFLD.

Identification of Anti-Mycobacterial Biofilm Agents Based on the 2-Aminoimidazole Scaffold

Tuberculosis (TB) remains a significant global health problem for which new therapeutic options are sorely needed. The ability of the causative agent, Mycobacterium tuberculosis, to reside within host macrophages and form biofilm-like communities contributes to the persistent and drug-tolerant nature of the disease. Compounds that can prevent or reverse the biofilm-like phenotype have the potential to serve alongside TB antibiotics to overcome this tolerance, and decrease treatment duration. Using Mycobacterium smegmatis as a surrogate organism, we report the identification of two new 2-aminoimidazole compounds that inhibit and disperse mycobacterial biofilms, work synergistically with isoniazid and rifampicin to eradicate preformed M. smegmatis biofilms in vitro, are nontoxic toward Galleria mellonella, and exhibit stability in mouse plasma.

4-n-butyl benzoyl chloride synthesis method

The invention discloses a 4-n-butyl benzoyl chloride synthesis method. The 4-n-butyl benzoyl chloride synthesis method comprises the following steps: (1) taking dibenzoyl peroxide as a catalyst and triethanolamine as an auxiliary catalyst, enabling 4-n-butyl methylbenzene and chlorine to have a chlorination to prepare a crude product of 4-n-butyl trichlorotoluene; and (2) enabling the crude product of 4-n-butyl trichlorotoluene and 4-n-butyl benzoic acid to have an acylation reaction with the participation of a catalyst ferric trichloride to prepare a target product 4-n-butyl benzoyl chloride.The fuming material oxalyl chloride is not needed, chlorine is introduced into the 4-n-butyl methylbenzene to generate 4-n-butyl trichlorotoluene, the 4-n-butyl trichlorotoluene and the 4-n-butyl benzoic acid are then reacted to generate the 4-n-butyl benzoyl chloride, the reaction operation is safe and simple, less three wastes are produced, no pollution to the environment is caused, the total yield of the product is more than 94%, the purity is more than 96%, and the method is suitable for industrial production.

Lanthanoid complexes supported by retro-Claisen condensation products of β-triketonates

β-Triketonates have been recently used as chelating ligands for lanthanoid ions, presenting unique structures varying from polynuclear assemblies to polymers. In an effort to overcome low solubility of the complexes of tribenzoylmethane, four β-triketones with higher lipophilicity were synthesised. Complexation reactions were performed for each of these molecules using different alkaline bases in alcoholic media. X-ray diffraction studies suggested that the ligands were undergoing decomposition under the reaction conditions. This is proposed to be caused by in situ retro-Claisen condensation reactions, consistent with two examples that have been reported previously. The lability of the lanthanoid cations in the presence of a varying set of potential ligands gave rise to structures where one, two, or three of the molecules involved in the retro-Claisen condensation reaction were linked to the lanthanoid centres. These results, along with measurements of ligand decomposition in the presence of base alone, suggest the solvent used will modulate the impact of the retro-Claisen condensation in these complexes.

Acid Chloride Synthesis by the Palladium-Catalyzed Chlorocarbonylation of Aryl Bromides

We report a palladium-catalyzed method to synthesize acid chlorides by the chlorocarbonylation of aryl bromides. Mechanistic studies suggest the combination of sterically encumbered PtBu3 and CO coordination to palladium can rapidly equilibrate the oxidative addition/reductive elimination of carbon-halogen bonds. This provides a useful method to assemble highly reactive acid chlorides from stable and available reagents, and can be coupled with subsequent nucleophilic reactions to generate new classes of carbonylated products. The Good, the Bad and the Bulky! By employing a sterically encumbered phosphine ligand, tri-tert-butyl phosphine, under palladium catalysis inert aryl bromides are chlorocarbonylated to create reactive acid chlorides by reversible carbon-halogen bond reductive elimination. This general platform allows for an expanded scope of the Heck carbonylation reaction to include previously incompatible nucleophiles.